1064. Treatment Success in Reducing Recurrent Clostridioides difficile Infection with Investigational Live Biotherapeutic RBX2660 Is Associated with Microbiota Restoration: Consistent Evidence from a Phase 3 Clinical Trial

BACKGROUND: Several investigational microbiota-based live biotherapeutics are in clinical development for reducing recurrence of Clostridioides difficile infection (rCDI), including RBX2660 a liquid suspension of a broad consortium of microbiota, which includes Bacteridetes and Firmicutes. RBX2660 h...

Descripción completa

Detalles Bibliográficos
Autores principales: Blount, Ken, Walsh, Dana M, Gonzalez, Carlos, Shannon, Bill
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644313/
http://dx.doi.org/10.1093/ofid/ofab466.1258

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644313/
http://dx.doi.org/10.1093/ofid/ofab466.1258

Ejemplares similares